AGIOS PHARMACEUTICALS, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2024-02-15
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-09-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2021-09-30 was -$0.08.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2023 was $0.00.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2021 was $32.45, a 108066.67% increase from fiscal 2020.
- AGIOS PHARMACEUTICALS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2020 was $0.03.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $32.45 10-K · filed 2024-02-15 | |||
| 2021-09-30 | -$0.08 10-Q · filed 2022-11-03 | $31.31 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$0.06 10-Q · filed 2022-08-04 | $30.05 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $28.26 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.03 10-K · filed 2023-02-23 | |||
| 2020-09-30 | -$0.29 10-Q · filed 2021-11-03 | $0.22 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$0.13 10-Q · filed 2021-07-29 | $0.51 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.64 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | -$1.84 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |